How often should a postmenopausal woman or an older adult with a history of fractures or on long-term steroid therapy undergo a bone density exam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Bone Density Exam Frequency

For postmenopausal women and older adults, bone density testing frequency depends on baseline bone density and risk factors: screen every 15 years for normal bone density, every 5 years for moderate osteopenia, annually for advanced osteopenia, and every 2-3 years for those on long-term steroids or with history of fractures.

Initial Screening Recommendations

  • All postmenopausal women aged ≥65 years should undergo routine DXA screening regardless of risk factors 1
  • Postmenopausal women aged 60-64 years with risk factors (low body weight <70 kg, previous fragility fracture, long-term glucocorticoid therapy, family history, or medical conditions causing bone loss) should be screened 1
  • Men aged ≥70 years should undergo screening 2
  • Younger postmenopausal women (<60 years) without risk factors do not need routine screening 1

Rescreening Intervals Based on Baseline Bone Density

The frequency of repeat testing is determined by your initial T-score, as bone loss progresses at different rates:

For Women with Normal Bone Density (T-score ≥-1.0)

  • Repeat DXA every 15-17 years 3
  • This extended interval is justified because less than 10% of women with normal bone density will develop osteoporosis within 15 years 3

For Women with Mild Osteopenia (T-score -1.01 to approximately -1.5)

  • Repeat DXA every 15-17 years 3
  • Similar to normal bone density, progression to osteoporosis is slow in this group 3

For Women with Moderate Osteopenia (T-score approximately -1.5 to -2.0)

  • Repeat DXA every 5 years 3
  • This group has accelerated bone loss requiring more frequent monitoring 3

For Women with Advanced Osteopenia (T-score -2.0 to -2.49)

  • Repeat DXA annually 3
  • These patients are at imminent risk of transitioning to osteoporosis and require close surveillance 3

Special Populations Requiring More Frequent Testing

Patients on Long-Term Glucocorticoid Therapy

For adults ≥40 years on chronic steroids:

  • Obtain baseline BMD within 6 months of starting glucocorticoid treatment 4, 5
  • If never treated with osteoporosis medication: Repeat DXA every 1-3 years, with earlier testing (annually) if receiving very high-dose glucocorticoids (prednisone ≥30 mg/day) or have history of osteoporotic fracture 5
  • If currently on osteoporosis treatment: Repeat DXA every 2-3 years during treatment, particularly for high-risk patients 5
  • If completed osteoporosis treatment: Repeat DXA every 2-3 years 4, 5

For adults <40 years on chronic steroids:

  • Obtain baseline BMD within 6 months if history of previous osteoporotic fracture or other significant risk factors 4
  • If Z-score <-3 at hip or spine, >10% annual BMD loss, or on very high-dose glucocorticoids: Repeat DXA every 1-3 years whether treated or untreated 5

Patients with History of Fractures

  • Patients with previous fragility fractures require more intensive monitoring 6
  • Repeat DXA every 1-2 years if on treatment to monitor effectiveness 1
  • If not on treatment but have fracture history, follow the glucocorticoid guideline intervals (every 1-3 years) 5

Clinical Factors That Shorten Rescreening Intervals

Beyond baseline bone density, several clinical situations mandate more frequent testing:

  • New glucocorticoid therapy or other bone-depleting medications 6
  • Incident fragility fracture 6
  • Development of secondary causes of bone loss (hyperparathyroidism, hypogonadism, chronic inflammatory diseases) 6
  • Significant weight loss, particularly if weight drops below 70 kg 6
  • Poor medication adherence or absorption concerns 5
  • Osteoporotic fracture occurring after ≥18 months of antifracture medication treatment 5

Technical Considerations

  • A minimum 2-year interval between scans is required to reliably detect true bone density changes due to precision limitations of DXA technology 6, 1
  • Scanning more frequently than every 2 years may lead to false conclusions about bone loss or gain 6
  • The yield of repeated screening is higher in older women, those with lower baseline BMD, and those with additional fracture risk factors 6, 1

Common Pitfalls to Avoid

  • Do not order DXA more frequently than every 2 years unless there are exceptional circumstances, as the test precision cannot reliably detect changes in shorter intervals 6, 1
  • Do not use the same rescreening interval for all patients—tailor the frequency to baseline T-score and risk factors 3
  • Do not forget annual clinical fracture risk reassessment (history, physical exam, falls evaluation) even when not performing DXA 4, 5
  • Do not neglect screening in men ≥70 years or those on chronic glucocorticoids, as osteoporosis is underdiagnosed and undertreated in men 7, 2

References

1
Guideline

Osteoporosis Screening and Diagnosis in Postmenopausal Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6
Guideline

Rescreening Intervals for Osteopenia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

When should medication be started to treat low bone mass?
When should someone get a repeat bone density scan if their first one was normal?
Interpret the DXA results (lumbar spine BMD 1.069 g/cm², T‑score ‑1.3; left femoral neck BMD 0.775 g/cm², T‑score ‑2.3; left total hip BMD 0.851 g/cm², T‑score ‑1.7) and FRAX 10‑year major osteoporotic fracture risk 4.3 % and hip fracture risk 1.1 % for a man aged 50 years or older, and provide management recommendations.
What is the interpretation of the lumbar spine and femoral neck bone mineral density results and the recommended treatment for a 65‑year‑old woman with lumbar spine osteoporosis (T‑score –2.7) and femoral‑neck osteopenia (T‑score –1.7) according to WHO classification and the National Osteoporosis Foundation guidelines?
How often should a bone density scan be done in patients with osteopenia?
What is the recommended treatment for a 13-month-old patient with asthma?
What is the initial treatment approach for an infant under 12 months old with asthma symptoms?
What is the recommended dosage of vancomycin (Vancomycin) for a 53kg patient with normal creatinine levels and severe diabetic foot infection requiring below-knee amputation?
What are the typical growth spurts for children from infancy through adolescence?
What is the proper use and dosage of Rocuronium (non-depolarizing neuromuscular blocking agent) in a patient with impaired renal function?
What is the protocol for continuous platelet transfusion in a patient requiring ongoing transfusions to manage thrombocytopenia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.